AU2002230922B2 - Non-invasive method for detecting target RNA - Google Patents

Non-invasive method for detecting target RNA Download PDF

Info

Publication number
AU2002230922B2
AU2002230922B2 AU2002230922A AU2002230922A AU2002230922B2 AU 2002230922 B2 AU2002230922 B2 AU 2002230922B2 AU 2002230922 A AU2002230922 A AU 2002230922A AU 2002230922 A AU2002230922 A AU 2002230922A AU 2002230922 B2 AU2002230922 B2 AU 2002230922B2
Authority
AU
Australia
Prior art keywords
heteroduplex
oligomer
antisense
sequence
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002230922A
Other languages
English (en)
Other versions
AU2002230922A1 (en
Inventor
Patrick L Iversen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sarepta Therapeutics Inc
Original Assignee
AVI Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AVI Biopharma Inc filed Critical AVI Biopharma Inc
Publication of AU2002230922A1 publication Critical patent/AU2002230922A1/en
Application granted granted Critical
Publication of AU2002230922B2 publication Critical patent/AU2002230922B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6832—Enhancement of hybridisation reaction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2002230922A 2000-12-13 2001-12-13 Non-invasive method for detecting target RNA Ceased AU2002230922B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/736,920 US20010024783A1 (en) 1999-01-29 2000-12-13 Non-invasive method for detecting target RNA
US09/736,920 2000-12-13
PCT/US2001/048694 WO2002048405A2 (en) 2000-12-13 2001-12-13 Non-invasive method for detecting target rna

Publications (2)

Publication Number Publication Date
AU2002230922A1 AU2002230922A1 (en) 2002-08-29
AU2002230922B2 true AU2002230922B2 (en) 2007-11-29

Family

ID=24961869

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002230922A Ceased AU2002230922B2 (en) 2000-12-13 2001-12-13 Non-invasive method for detecting target RNA
AU3092202A Pending AU3092202A (en) 2000-12-13 2001-12-13 Non-invasive method for detecting target rna

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU3092202A Pending AU3092202A (en) 2000-12-13 2001-12-13 Non-invasive method for detecting target rna

Country Status (7)

Country Link
US (2) US20010024783A1 (enExample)
EP (1) EP1356110A2 (enExample)
JP (1) JP2004537030A (enExample)
KR (1) KR20030070584A (enExample)
AU (2) AU2002230922B2 (enExample)
CA (1) CA2431646A1 (enExample)
WO (1) WO2002048405A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050159381A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
US20030082594A1 (en) * 2001-08-08 2003-05-01 Gabe Christopher J. System and method for analyzing resistance of a pathogen to one or more treatments
WO2003040411A1 (en) * 2001-11-05 2003-05-15 Transgenomic, Inc. Methods, systems, and kits for analysis of polynucleotides
US20090093439A1 (en) * 2002-02-20 2009-04-09 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2007030691A2 (en) * 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
JP5850519B2 (ja) 2011-05-09 2016-02-03 ネッパジーン株式会社 モルフォリノ搭載バブルリポソームを有効成分としてなる筋ジストロフィー治療薬
CA2838053A1 (en) * 2011-06-03 2012-12-06 University Of South Alabama Methods and compositions for detecting endometrial or ovarian cancer
CN102559888A (zh) * 2011-12-27 2012-07-11 芮屈生物技术（上海）有限公司 癌变前期CPE的mRNA水平原位杂交检测试剂盒及检测方法和应用
WO2016179043A1 (en) * 2015-05-01 2016-11-10 Dermtech, Inc. Non-invasive skin collection system
WO2021150997A2 (en) * 2020-01-22 2021-07-29 Engene, Inc. Localized expression of therapeutic nucleic acids in lung epithelial cells
US20240318242A1 (en) * 2022-01-28 2024-09-26 City University Of Hong Kong Methods and systems for measuring multiplex rna expression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009033A1 (en) * 1989-12-20 1991-06-27 Anti-Gene Development Group Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
WO2000044897A1 (en) * 1999-01-29 2000-08-03 Avi Biopharma, Inc. Method of treating restenosis by antisense targeting of c-myc

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009033A1 (en) * 1989-12-20 1991-06-27 Anti-Gene Development Group Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
WO2000044897A1 (en) * 1999-01-29 2000-08-03 Avi Biopharma, Inc. Method of treating restenosis by antisense targeting of c-myc

Also Published As

Publication number Publication date
US20030171328A1 (en) 2003-09-11
WO2002048405A2 (en) 2002-06-20
AU3092202A (en) 2002-06-24
US20010024783A1 (en) 2001-09-27
EP1356110A2 (en) 2003-10-29
WO2002048405A3 (en) 2003-08-21
JP2004537030A (ja) 2004-12-09
CA2431646A1 (en) 2002-06-20
KR20030070584A (ko) 2003-08-30

Similar Documents

Publication Publication Date Title
AU778057B2 (en) Non-invasive method for detecting target RNA
Younes et al. Labelled oligonucleotides as radiopharmaceuticals: pitfalls, problems and perspectives
EP0736093B1 (en) ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB-2 PLAYS A ROLL
US6057437A (en) Antisense nucleic acid compounds inhibiting vascular endothelial growth factor
JP4643906B2 (ja) 遺伝子発現の標的化阻害のための合成二本鎖オリゴヌクレオチド
Tavitian In vivo imaging with oligonucleotides for diagnosis and drug development
US20030171328A1 (en) Non-invasive method for detecting target-RNA
Bennett Efficiency of antisense oligonucleotide drug discovery
WO2013142735A1 (en) Targeting domain and related signal activated molecular delivery
AU2002230922A1 (en) Non-invasive method for detecting target RNA
Rapozzi et al. Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids
Sorets et al. Elucidating brain transport pathways and cell type-dependent gene silencing of a durable lipid–siRNA conjugate administered into cerebrospinal fluid
US20140309280A1 (en) Assays for micro-rna-182 as a biomarker for muscle atrophy and therapeutic applications
AU767490B2 (en) Method for quantitating oligonucleotides
US6333177B1 (en) Selective technique for rapid identification of proteins and genes and uses thereof
Ivanov et al. Artificial genetic polymers against human pathologies
JP7127224B1 (ja) プローブを使用したオリゴヌクレオチドの検出方法
Kenguva et al. Cell-SELEX technology for aptamer selection
JP2003507037A (ja) プロパンジオールを含有するキメラｄｎａ／ｒｎａリボザイム
JP7691163B2 (ja) プローブを使用したオリゴヌクレオチドの検出方法
CN118931908A (zh) 一种结合蛋白磷酸酶1调节亚基26蛋白的核酸适配体、筛选方法及其应用
CN114729364A (zh) 用于沉默肿瘤中的人l1-met转录物的反义寡核苷酸序列
HK40077247A (en) Antisense oligonucleotide sequences for silencing the human l1-met transcript in tumours
CN119955791A (zh) 一种结合cd86蛋白的核酸适配体及其应用
Tavitian In vivo imaging with oligonucleotides for diagnosis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired